A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. - Wikidata - wikimedia - TriplyDB

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

http://www.wikidata.org/entity/Q37005569

about

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives Trabectedin in soft tissue sarcomas Trabectedin for the management of soft-tissue sarcoma.New developments in treatment of ovarian carcinoma: focus on trabectedin Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres.Role of trabectedin in the treatment of soft tissue sarcoma Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Pegylated liposomal doxorubicin in the management of ovarian cancer Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies Trabectedin: an anticancer drug from the sea.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.Trabectedin for the treatment of breast cancer.Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.The efficacy of trabectedin in treating ovarian cancer.The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Efficacy of trabectedin for the treatment of liposarcoma.Challenging issues in molecular-targeted therapy.Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

P2860

Q26745502-533E1AAA-1A19-48C6-BA9D-71802A3D91A2 Q28085505-DEA712CC-0746-43CC-8132-C40380B3E2C1 Q33384836-9C253AE1-5FF8-4895-9AF0-804D7707EA90 Q33393429-3FA0759E-D605-4B13-AC76-8B094AA663A6 Q33416931-1DB414F4-C21A-4A31-A540-81633D20EA1C Q33723424-4FC04748-927E-4B0F-AC87-30673CFFD878 Q33916011-67A7E58A-A164-4ADE-8DDE-D34D1A0F9010 Q33921802-F526B7A8-B202-45AF-A2EF-5BD19E0C1E48 Q34187661-3AA0D32E-CBCB-49DD-A32B-8A7FB68610CA Q34413664-4BD46865-78A5-4467-9D2E-AA0900ED78EB Q35246995-6C5D5A5D-E2AE-4B6A-A4FC-C796E83C929F Q36728989-624E0C2C-F75C-408E-B47C-3214E04DB8A7 Q37163139-4C9C39F2-3697-4190-A05C-53126C24F99A Q37594790-0F689B38-4B56-45F7-8762-8C93F45DD673 Q37760957-7EBA2F64-0D4E-4FE0-BB85-D69101D34422 Q37765581-1AE2AE82-5B38-45DD-A12D-350976440AA0 Q37857281-9134577C-F533-4E28-A893-24E0FC4724B7 Q38642314-8F99F103-74C5-47B1-9D48-F322C1664B2E Q38731757-7AD09D50-8A3B-44C3-835C-9403C1CFCB14 Q38763841-FD7E67B7-5E27-4D90-83E2-0F47AE31AC42 Q38797843-C7416382-6516-4B14-BB39-8ADC6A79009A Q38951318-C187B139-A2CA-45CA-8AD5-3657F1CB4465 Q41436013-F3D24254-E378-4BAB-9B9C-4B945F9A34DB Q47885855-7BEC4F2D-B911-474B-9BBA-8466F4316B85 Q55365628-1A4BD403-359C-4A57-9B8D-2EC1FF4BC156

P2860

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

http://www.wikidata.org/entity/Q37005569

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A phase I study of the safety ...... ts with advanced malignancies.

@en

A phase I study of the safety ...... ts with advanced malignancies.

@nl

type

label

A phase I study of the safety ...... ts with advanced malignancies.

@en

A phase I study of the safety ...... ts with advanced malignancies.

@nl

prefLabel

A phase I study of the safety ...... ts with advanced malignancies.

@en

A phase I study of the safety ...... ts with advanced malignancies.

@nl

P1433

Q37005569-B87007E0-E055-4054-8630-F5B045A1C233

P1476

Q37005569-FCEC5F5B-6849-475A-A355-695528098262

P2093

Q37005569-11C42174-5564-4E78-A892-4C69AA661C07

Q37005569-34B33421-5AF0-4384-A428-3B8E5C65A358

Q37005569-4009AB60-328D-4583-9FEB-F5ED2D30517F

Q37005569-436C8605-C726-41EE-B778-CFCE2DE07D14

Q37005569-88E46E3C-1F56-44CC-8D4A-43A58CD59DA3

Q37005569-A8D02E9A-9401-4F54-B62C-832E5F48F264

Q37005569-B02236BF-0525-4CFB-B7F0-BF98FEEFA802

Q37005569-B5951036-B522-4DBC-9FCE-D5306BAA110D

Q37005569-DF5620BF-26ED-40F3-BC01-437D421F37F5

Q37005569-E5191392-11CB-47D8-BC86-DCB491971399

P2860

Q37005569-03047FBC-8CEE-4F87-A86A-BB4B71011B8C

Q37005569-076E58C0-FB22-4E44-8B92-0D594D281DC4

Q37005569-0D21F6F6-C2B8-46F1-8E70-4A5113FCEE42

Q37005569-20230BAF-BEAB-43BD-8F07-29161BB404A8

Q37005569-25125F37-ECE2-458E-8C0F-4D3FE9403C84

Q37005569-2ACC0382-EAF7-4BDF-B3EB-D1E5FE45C118

Q37005569-33364456-9F92-44DF-8CE7-C4CE7B724B3E

Q37005569-47325F77-902B-48A8-BBBA-6D845B2FD21C

Q37005569-4AAC563B-3940-458D-9087-25C5F7377B00

Q37005569-4D81B49A-C32D-44C6-BAA6-AB46321CE2C8

P304

Q37005569-4868CCBD-C9FF-4CFD-BBC5-6A25B3F4F483

P31

Q37005569-2DCC423A-7EC7-4AEA-9133-208DD5E01066

P356

Q37005569-41EAC869-3FF2-42AE-866D-ED47DB8BA5E9

P433

Q37005569-2E9FEA4B-5848-4828-9679-842CA24FF21F

P478

Q37005569-7D668FA4-70C5-4440-8CA6-D7F1D1AEF7FB

P577

Q37005569-2DF5AA0F-8B37-4930-BE96-2B7B4A0E29EB

P5875

Q37005569-ED990452-9E44-4FFD-8EC0-8D1A4869E902

P698

Q37005569-3BBC7F4F-A1C7-40AB-AC8D-B116CCAE5834

P921

Q37005569-941A5BEB-0A5F-432A-92AC-3B58C4AC8176

P932

Q37005569-E50C8BFC-B801-4639-BB23-A87111EBEFB1

P356

P1433

Annals of Oncology

P1476

A phase I study of the safety ...... ts with advanced malignancies.

@en

P2093

E Bayever

http://www.w3.org/2001/XMLSchema#string

E Temmer

http://www.w3.org/2001/XMLSchema#string

F G Renshaw

http://www.w3.org/2001/XMLSchema#string

J D Cheng

http://www.w3.org/2001/XMLSchema#string

M von Mehren

http://www.w3.org/2001/XMLSchema#string

P Zannikos

http://www.w3.org/2001/XMLSchema#string

R B Cohen

http://www.w3.org/2001/XMLSchema#string

R J Schilder

http://www.w3.org/2001/XMLSchema#string

T M Cardoso

http://www.w3.org/2001/XMLSchema#string

Z Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

P304

1802-1809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN363

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5353713

http://www.w3.org/2001/XMLSchema#string

P698

18497430

http://www.w3.org/2001/XMLSchema#string

P921

P932

2598415

http://www.w3.org/2001/XMLSchema#string